Hair Loss News and Research

RSS

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

UHCMC now offers HITEC for women with gynecologic cancers

Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

21 Jan 2012

Researchers discover HS1.2 enhancer as the cause of SLE

A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.

17 Jan 2012

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Halaven (eribulin mesylate) Injection.

4 Jan 2012

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Scientists pinpoint central elements of cell division

Scientists at Warwick Medical School have uncovered the molecular process of how cells are by-passing the body's inbuilt 'health checkpoint' with cells that carry unequal numbers of chromosomes that have a higher risk of developing cancer.

2 Nov 2011

New potential leukemia therapy targets and kills cancer cells

A new potential leukemia therapy targets only cancer cells, while leaving healthy cells alone. Many current chemotherapy treatments affect cancer cells and healthy cells, causing significant side effects, such as fatigue, hair loss, nausea, anxiety and depression.

27 Oct 2011

Women more likely to develop lupus at earlier ages

Debilitating. Destructive. Life-altering. These are just a few words used to describe autoimmune disease. Autoimmune diseases affect women 8 times more often than men, with lupus being one of the most disruptive. Lupus is a disease that occurs when a person's immune system attacks its own tissues and organs instead of attacking foreign invaders such as common viruses and bacteria. Lupus often results in wide-spread inflammation, pain, swelling and organ/tissue damage throughout the body.

19 Oct 2011

HHWC medical doctors provide insight into depression

A staggering 230 million antidepressant prescriptions are filled each year. Yet the face of depression does not always fit the mold: a successful career, loving spouse, wonderful children, seemingly good health and finances. From the outside life appears perfect, so why are Americans depressed?

15 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Hair loss, divorce and smoking in women – links established

A new study showed that genetics aside, the next strongest predictor of midline (central) hair loss among women is their marital status, with the loss of a spouse (through either divorce or death) raising the risk for thinning hair above that of married or single women.

26 Sep 2011

HealthWell Foundation introduces new lupus fund

The HealthWell Foundation, a nonprofit organization providing financial assistance to insured patients facing a variety of chronic and life-altering illnesses, announces the launch of a new fund supporting treatment for Systemic Lupus Erythematosus (SLE), the most common form of lupus.

22 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

Scientists invent new system that uses magnetism to purify hybrid nanoparticles

A team of Penn State University scientists has invented a new system that uses magnetism to purify hybrid nanoparticles -- structures that are composed of two or more kinds of materials in an extremely small particle that is visible only with an electron microscope.

8 Sep 2011

Stem cell therapy for baldness

Researchers have found that molecular signals from stem cells within the skin's fatty layer trigger hair growth in mice. This could mean new treatments for baldness in people.

5 Sep 2011